Compare ZLAB & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZLAB | AGIO |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | 2017 | 2013 |
| Metric | ZLAB | AGIO |
|---|---|---|
| Price | $18.35 | $28.04 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $49.60 | $38.88 |
| AVG Volume (30 Days) | 598.6K | ★ 1.2M |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.46 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $460,156,000.00 | $43,011,000.00 |
| Revenue This Year | $9.75 | $76.75 |
| Revenue Next Year | $26.03 | $170.73 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.33 | N/A |
| 52 Week Low | $15.96 | $22.24 |
| 52 Week High | $44.34 | $46.00 |
| Indicator | ZLAB | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 35.16 | 47.46 |
| Support Level | $16.88 | $26.64 |
| Resistance Level | $19.64 | $29.39 |
| Average True Range (ATR) | 0.95 | 1.15 |
| MACD | -0.51 | 0.03 |
| Stochastic Oscillator | 0.22 | 84.33 |
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.